Three ingredients dominate dog calming products: melatonin, L-theanine, and alpha-casozepine. Each has real research, and each has clear limits. Here is what the peer-reviewed dog evidence actually shows — graded, not hyped.
Melatonin
Melatonin suits situational and sleep-related use. It is not proven to treat everyday anxiety, and a dermatology study found melatonin implants did not reliably prevent flank alopecia recurrence (Verschuuren 2022).
L-theanine
L-theanine is the calming active with some of the more consistent dog data, typically for daytime background anxiety rather than sleep.
Alpha-casozepine
Alpha-casozepine may help some dogs in some situations, but the effect is inconsistent and does not reliably calm the body’s physiological stress response.
The honest limit: finished blends are not the same as ingredients
Every study above tested a single ingredient (or a specific product) in a specific setting. None of them proves that a particular multi-ingredient retail chew or liquid works, or that the amount in a given product is effective. That includes the six-active Pure Majesty formula: the individual ingredients have the evidence described here, but the finished blend has not been tested in a published canine trial.
| Active ingredient | Per 1 mL |
|---|---|
| Melatonin | 3 mg |
| L-theanine | 50 mg |
| Alpha-casozepine | 25 mg |
| Water-soluble chamomile extract | 25 mg |
| Elemental magnesium | 5 mg |
| Vitamin B6 (as P5P) | 0.5 mg |
Pure Majesty publishes this six-active formula on its product page (labeled per 1 mL, updated July 2026); confirm the panel printed on the bottle you receive. Ingredient amounts describe what is in the bottle; they do not by themselves prove a calming or sleep outcome, and this exact six-active blend has not been tested in a published canine clinical trial.
How to use this when choosing a product
- Prefer products that disclose the amount of each active, so you can compare to studied amounts.
- Match the ingredient to the problem — melatonin for situational/sleep, L-theanine for daytime anxiety.
- Treat “clinically proven” claims on finished blends with skepticism unless the product itself was tested.
Frequently asked questions
Which calming ingredient has the best evidence in dogs?
Is alpha-casozepine proven to calm dogs?
Does combining these ingredients work better?
Sources
- Niggemann JR, Tichy A, Eberspächer-Schweda MC, Eberspächer-Schweda E. Preoperative calming effect of melatonin and its influence on propofol dose for anesthesia induction in healthy dogs. Veterinary Anaesthesia and Analgesia. 2019;46(5):560–567. doi:10.1016/j.vaa.2019.02.009
- Costa RS, Jones T, Robbins S, Stein A, Borns-Weil S. Gabapentin, melatonin, and acepromazine combination prior to hospital visits decreased stress scores in aggressive and anxious dogs in a prospective clinical trial. JAVMA. 2023;261(11):1660–1665. doi:10.2460/javma.23.02.0067
- Araujo JA, de Rivera C, Ethier JL, et al. ANXITANE tablets reduce fear of human beings in a laboratory model of anxiety-related behavior. Journal of Veterinary Behavior. 2010;5(5):268–275. doi:10.1016/j.jveb.2010.02.003
- Pike AL, Horwitz DF, Lobprise H. An open-label prospective study of the use of L-theanine (Anxitane) in storm-sensitive client-owned dogs. Journal of Veterinary Behavior. 2015;10(4):324–331. doi:10.1016/j.jveb.2015.04.001
- Schroers M, Juhasz A, Zablotski Y, Meyer-Lindenberg A. Effect of casozepine administration on stress in dogs during a veterinary examination—a randomized placebo-controlled trial. The Veterinary Journal. 2024;306:106148. doi:10.1016/j.tvjl.2024.106148
- Puglisi I, Masucci M, Siracusa C. Efficacy of alpha-casozepine in reducing dogs’ anxiety during veterinary visits: a randomized, fully-blinded, placebo-controlled study. Journal of Veterinary Behavior. 2026;84:1–8. doi:10.1016/j.jveb.2025.12.008
- Verschuuren MUMY, Schlotter YM, van Geijlswijk IM, van der Lugt JJ, Gehring R. The efficacy of subcutaneous slow-release melatonin implants in the prevention of canine flank alopecia recurrence is uncertain. Veterinary Dermatology. 2022;33(6):553–558. doi:10.1111/vde.13122